{"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0195","statisticalMethod":"Cochran-Mantel-Haenszel","testedNonInferiority":false}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"48.0","upperLimit":"58.9","value":"170"},{"groupId":"OG001","value":"70"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"318"},{"groupId":"OG001","value":"157"}],"units":"Participants"}],"description":"ACR20 response was defined as a ≥ 20% improvement compared with baseline in both tender joint count (TJC) \\[68 joints\\] and swollen joint count (SJC) \\[66 joints\\] as well as a ≥ 20% improvement in three of five additional measurements: 1) Physician's Global Assessment of disease activity \\[visual analog scale: 0=no disease activity to 100=maximum disease activity\\]; 2) Patient's Global Assessment of Disease Activity \\[visual analog scale: 0=no disease activity to 100=maximum disease activity\\]; 3) Patient's Assessment of Pain \\[visual analog scale: 0=no pain to 100=unbearable pain\\]; 4) Health Assessment Questionnaire \\[20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities, 0=without difficulty to 3=unable to do\\] and 5) erythrocyte sedimentation rate.","groups":[{"description":"1000 mg rituximab intravenous initial treatment on day 1 and day 15 plus 10-25 mg/week methotrexate followed by re-treatment during weeks 24 -40 consisting of two additional doses of 1000 mg rituximab 14 days apart plus 10-25 mg/week methotrexate.","id":"OG000","title":"Arm A: Rituximab Retreatment"},{"description":"1000 mg rituximab initial treatment on day 1 and day 15 plus 10-25 mg/wk methotrexate followed by re-treatment during weeks 24 -40 consisting of two doses of placebo 14 days apart plus 10-25 mg/wk methotrexate.","id":"OG001","title":"Arm B: Placebo Retreatment"}],"paramType":"NUMBER","populationDescription":"Intent-to-treat population includes all participants randomized to Retreatment.","reportingStatus":"POSTED","timeFrame":"48 Weeks","title":"Retreated Subjects With an American College of Rheumatology 20% (ACR20) Response at Week 48 Relative to Baseline","type":"PRIMARY","unitOfMeasure":"Participants"}